FDA approves prostate cancer treatment that inhibits testosterone synthesis

Thompson, Cheryl A.
June 2011
American Journal of Health-System Pharmacy;6/1/2011, Vol. 68 Issue 11, p960
Academic Journal
No abstract available.


Related Articles

  • Regorafenib Tablets (Stivarga®). Elliott, William T.; Chan, James // Internal Medicine Alert;4/15/2013, Vol. 35 Issue 7, p53 

    The article reports on the approval by the Food and Drug Administration of an oral multikinase inhibitor regorafenib which is marketed by Bayer HealthCare Pharmaceuticals as Stivarga, for the treatment of metastatic colorectal cancer and advanced gastrointestinal stromal tumors.

  • Eribulin approved for advanced breast cancer. Traynor, Kate // American Journal of Health-System Pharmacy;1/1/2011, Vol. 68 Issue 1, p6 

    The article reports that Eisai Inc. and the U.S. Food & Drug Administration (FDA) have announced that eribulin mesylate injection can be used for the treatment of metastatic breast cancer. This would be applicable to patients who have previously undergone treatment with an anthracycline and a...

  • U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. YANG-MIN NING; BRAVE, MICHAEL; MAHER, V. ELLEN; LIJUN ZHANG; SHENGHUI TANG; SRIDHARA, RAJESHWARI; KIM, GEOFFREY; IBRAHIM, AMNA; PAZDUR, RICHARD // Oncologist;2015, Vol. 20 Issue 8, p960 

    The U.S. Food and Drug Administration approved enzalutamide for the treatment of patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). At the prespecified interim analysis, a statistically significant improvement in overall survival was demonstrated for...

  • Ipilimumab approved for metastatic melanoma. Traynor, Kate // American Journal of Health-System Pharmacy;5/1/2011, Vol. 68 Issue 9, p768 

    The article reports that the Food and Drug Administration (FDA) approved ipilimumab, to be marketed as 'Yervoy' by Bristol-Myers Squibb, for the treatment of metastatic melanoma. It offers information on the product, an immunoglobulin G1&subk; (IgG1&subk;) monoclonal antibody, which binds to the...

  • Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date. Lemech, Charlotte; Infante, Jeffrey; Arkenau, Hendrik-Tobias // Drugs;2013, Vol. 73 Issue 8, p767 

    Previously characterized by a median overall survival of between 6 and 12 months, metastatic melanoma now has a number of novel and effective treatment options. The ability to target the mitogen-activated protein kinase (MAPK) pathway with BRAF (v-raf murine sarcoma viral oncogene homolog B1) or...

  • FDA actions in brief.  // Formulary;Jul2010, Vol. 45 Issue 7, p207 

    The article presents U.S. Food and Drug Administration news briefs that Namenda XR (Memantine hydrochloride) was approved to treat Alzheimer's type dementia, Tasigna (Nilotinib) was approved for chronic myeloid leukemia and ranibizumab injection (Lucentis) was approved for the treatment of...

  • Ibrutinib: First Global Approval. Cameron, Fiona; Sanford, Mark // Drugs;Feb2014, Vol. 74 Issue 2, p263 

    Ibrutinib (Imbruvicaâ„¢) is a small molecule, first-in-class, once-daily, orally available, Bruton's tyrosine kinase inhibitor that is under development for the treatment of B cell malignancies, including chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and diffuse large B...

  • Approval Summary: Pemetrexed Maintenance Therapy of Advanced/Metastatic Nonsquamous, Non-Small Cell Lung Cancer (NSCLC). COHEN, MARTIN H.; CORTAZAR, PATRICIA; JUSTICE, ROBERT; PAZDUR, RICHARD // Oncologist;Dec2010, Vol. 15 Issue 12, p1352 

    On July 2, 2009, the U.S. Food and Drug Administration approved pemetrexed injection (Alimta® Injection; Eli Lilly and Company, Indianapolis, IN) for maintenance treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed...

  • AS WE SEE IT. FDA Delay of One Drug Causes 82,000 Lost Life-Years. FALOON, WILLIAM // Life Extension;Nov2010, Vol. 16 Issue 11, p7 

    In this article the author discusses the impact that a delay in the approval process of the U.S. Food and Drug Administration regarding the drug Provenge had on male patients with prostate cancer. He is critical of the administration's approval process and its impact on cancer drug development....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics